VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
VM Oncology, LLC
VM Oncology, LLC
LigaChem Biosciences, Inc.
Klus Pharma Inc.
Stanford University
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)